The Clinical Utility of Biomarkers in Diagnosing Major Depressive Disorder in Adults: A Systematic Review of Literature From 2013 to 2023
Psychiatry Investigation · 25.04.2025 · 22 (4) · 341-356
DOI: 10.30773/pi.2024.0152 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Psychiatry Investigation, erschienen am 25.04.2025. Verfasst von Shi-Han Ang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, National University of Singapore, Singapore. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Anhui University.
Abstract (Originalsprache)
Objective
The variety and efficacy of biomarkers available that may be used objectively to diagnose major depressive disorder (MDD) in adults are unclear. This systematic review aims to identify and evaluate the variety of objective markers used to diagnose MDD in adults.
Methods
The search strategy was applied via PubMed and PsycINFO over the past 10 years (2013–2023) to capture the latest available evidence supporting the use of biomarkers to diagnose MDD. Data was reported through narrative synthesis.
Results
Forty-two studies were included in the review. Findings were synthesised based on the following measures: blood, neuroimaging/neurophysiology, urine, dermatological, auditory, vocal, cerebrospinal fluid and combinatory—and evaluated based on its sensitivity/specificity and area under the curve values. The best predictors of blood (MYT1 gene), neuroimaging/neurophysiological (5-HT1A auto-receptor binding in the dorsal and median raphe), urinary (combined albumin, AMBP, HSPB, APOA1), cerebrospinal fluid-based (neuron specific enolase, microRNA) biomarkers were found to be closely linked to the pathophysiology of MDD.
Conclusion
A large variety of biomarkers were available to diagnose MDD, with the best performing biomarkers intrinsically related to the pathophysiology of MDD. Potential for future research lies in investigating the joint sensitivity of the best performing biomarkers identified via machine learning methods and establishing the causal effect between these biomarkers and MDD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychological Medicine, National University of Singapore, Singapore.
- Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore.
- Division of Life Science (LIFS), Hong Kong University of Science and Technology, Hong Kong.
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Förderung
- Anhui University
Zitieren
APA
Ang, S. H., Ho, R. C., McIntyre, R. S., Zhang, Z., Chang, S. K., Teopiz, K. M., & Ho, C. S. (2025). The Clinical Utility of Biomarkers in Diagnosing Major Depressive Disorder in Adults: A Systematic Review of Literature From 2013 to 2023. Psychiatry Investigation, 22(4), 341-356. https://doi.org/10.30773/pi.2024.0152
Vancouver
Ang SH, Ho RC, McIntyre RS, Zhang Z, Chang SK, Teopiz KM, et al. The Clinical Utility of Biomarkers in Diagnosing Major Depressive Disorder in Adults: A Systematic Review of Literature From 2013 to 2023. Psychiatry Investigation. 2025;22(4):341-356. doi:10.30773/pi.2024.0152
BibTeX
@article{Ang2025,
author = {Ang, Shi-Han and Ho, Roger C and McIntyre, Roger S and Zhang, Zhisong and Chang, Soon-Kiat and Teopiz, Kayla M and Ho, Cyrus Sh},
title = {The Clinical Utility of Biomarkers in Diagnosing Major Depressive Disorder in Adults: A Systematic Review of Literature From 2013 to 2023},
journal = {Psychiatry Investigation},
year = {2025},
volume = {22},
number = {4},
pages = {341--356},
doi = {10.30773/pi.2024.0152}
}
EUVIMED